GPCR

16.3004.79%
XL

Xichen Lin

Chief Scientific Officer & GM of Structure Shanghai

Dr. Xichen Lin, Ph.D., has been the Chief Scientific Officer at Structure Therapeutics Inc. (formerly known as ShouTi, Inc.) since July 2019 and has been General Manager of Shanghai ShouTi Biotechnology Co., Ltd. Dr. Lin has experience in drug discovery and development and has delivered multiple clinical candidates, including several Phase 2 assets. Prior to ShouTi, Dr. Lin worked at Novo Nordisk as Head of Asia Pacific External Innovation from May2016 to July 2019, responsible for identification and evaluation of external opportunities in the region. Prior to joining Novo Nordisk A/S, Dr. Lin served as Operation Partner at C-Bridge Capital. Given his expertise in small molecules, Dr. Lin also led the formation of a strategic alliance between Novo Nordisk and Evotec focused on small molecule drug discovery and development targeting diabetes and obesity. Dr. Lin started his professional career at GSK as a medicinal chemist and later transferred to Shanghai to build and lead the chemistry team. In this role, he led global drug discovery teams to deliver clinical candidates in various disease areas including COPD, asthma, multiple sclerosis and Alzheimer’s disease. Dr. Lin held various scientific and strategy roles at GlaxoSmithKline, or GSK, from July 2002 to December 2015, including Head of GSK Global Neuroinflammation Discovery Performance Unit. He ended his GSK tenure as Head of the Global Neuroinflammation Discovery Performance Unit, covering target identification through Phase 2 studies. Dr. Lin holds more than 30 patents and has authored more than 35 publications. He obtained a Ph.D. in Organic Chemistry from The Pennsylvania State University and a B.S. Chemistry from Peking University.

公司職務